Altina 250 mg (Tablet)

Title

• Altina Tablet

Categories

• Medicine
• Healthcare
• Pharmaceuticals

Description

• Altina tablet is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2)
• It is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors
• Recommended dosage consists of administration in combination with Capecitabine or Letrozole

Dimension

• Tablet size: standard

Color Options

• White

Functions

• Inhibits growth of ErbB-driven tumor cells
• Treats hormone receptor-positive metastatic breast cancer
• Inhibits CYP3A4, CYP2C8, and P-glycoprotein (P-gp, ABCB1) in vitro at clinically relevant concentrations

Materials

• Active ingredient: Lapatinib
• Inactive ingredients

Technical Specifications

• Dose: 1,250 mg
• Dosage form: Oral tablet
• Storage temperature: below 30°C

Design Elements

• Tablet shape: standard

Usability Features

• Recommended to be taken with or after a meal
• Should be taken at least one hour before or one hour after a meal

Indications

• Indicated in combination with Capecitabine for advanced or metastatic breast cancer overexpressing HER2
• Indicated in combination with Letrozole for hormone receptor-positive metastatic breast cancer overexpressing HER2

Pharmacology

• Acts as a kinase inhibitor of EGFR and HER2 receptors
• Exhibits incomplete and variable absorption following oral administration

Dosage & Administration

• Recommended dose of Lapatinib is 1,250 mg given orally once daily on Days 1-21 continuously in combination with Capecitabine 2,000 mg/m2/day
• Lapatinib should be taken at least one hour before or one hour after a meal

Interactions

• Inhibits various drug-metabolizing enzymes and drug transport systems
• Caution should be exercised when dosing concurrently with medications with narrow therapeutic windows

Contraindications

• Contraindicated in patients with known severe hypersensitivity to the product or any of its components

Side Effects

• Common adverse reactions during treatment include diarrhea, palmar-plantar erythrodysesthesia, nausea, rash, vomiting, and fatigue

Pregnancy & Lactation

• Can cause fetal harm when administered to a pregnant woman
• Advised not to breastfeed during treatment

Precautions & Warnings

• Reported to decrease Left Ventricular Ejection Fraction
• Hepatotoxicity observed in clinical trials
• Diarrhea has been reported, prompt treatment with antidiarrheal agents recommended

Use in Special Populations

• Dose modifications recommended for cardiac events, hepatic impairment, diarrhea, and concomitant drug interactions

Overdose Effects

• No known antidote for overdoses of Altina
• Maximum oral doses administered in clinical trials are 1,800 mg once daily

Therapeutic Class

• Cytotoxic Chemotherapy

Storage Conditions

• Store below 30°C in a dry place

Related Brands